Conivaptan
Conivaptan (YM 087 free base) is antagonist for vasopressin V1A receptor and vasopressin V2 receptor. Conivaptan ameliorates congestive heart failure, improves cardiac systolic function[1].
Product Specifications
CAS Number
210101-16-9
Product Name Alternative
YM 087 (free base)
UNSPSC
12352005
Hazard Statement
H302-H312-H332
Target
Vasopressin Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/conivaptan.html
Smiles
O=C(C1=C(C2=CC=CC=C2)C=CC=C1)NC3=CC=C(C(N4C5=C(C6=C(CC4)N=C(C)N6)C=CC=C5)=O)C=C3
Molecular Formula
C32H26N4O2
Molecular Weight
498.57
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501
References & Citations
[1]Wada K, et al., Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure. Eur J Pharmacol. 2005 Jan 10;507 (1-3) :145-51.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
V1a Receptor ; V2 Receptor
Citation 01
Biomed Pharmacother. 2025 Jun 20:189:118246.|Biomed J. 2020 Aug;43 (4) :368-374.|Dig Dis Sci. 2022 Aug;67 (8) :3683-3692.|Eur J Pharmacol. 2020 Aug 5;880:173157.|Front Pharmacol. 2019 Nov 15;10:1380.|J Med Chem. 2022 Jul 14;65 (13) :9295-9311.|J Med Chem. 2024 Apr 11;67 (7) :5935-5944.|J Pharm Biomed Anal. 2021 Feb 20:195:113870.|J Transl Med. 2025 Jan 22;23 (1) :103.|Nat Commun. 2025 Nov 4;16 (1) :9734.|Neurogastroenterol Motil. 2019 Feb;31 (2) :e13493.|SSRN. 2023 May 30.|SSRN. 2025 Jun 18.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
